125 related articles for article (PubMed ID: 37814391)
1. Unlocking the role of the B7-H4 polymorphism in psoriasis: Insights into methotrexate treatment outcomes: A prospective cohort study.
Wang B; Wang Z; Yang W; Han L; Huang Q; Yawalkar N; Zhang Z; Yao Y; Yan K
Immunology; 2024 Jan; 171(1):104-116. PubMed ID: 37814391
[TBL] [Abstract][Full Text] [Related]
2. B7-H4 Polymorphism Influences the Prevalence of Diabetes Mellitus and Pro-Atherogenic Dyslipidemia in Patients with Psoriasis.
Yang W; Huang Q; Han L; Wang B; Yawalkar N; Zhang Z; Yan K
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362461
[TBL] [Abstract][Full Text] [Related]
3. TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study.
Yan KX; Zhang YJ; Han L; Huang Q; Zhang ZH; Fang X; Zheng ZZ; Yawalkar N; Chang YL; Zhang Q; Jin L; Qian DF; Li XY; Wu MS; Xu QH; Zhang XJ; Xu JH
Br J Dermatol; 2019 Oct; 181(4):778-785. PubMed ID: 31020648
[TBL] [Abstract][Full Text] [Related]
4. The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients.
Fan Z; Zhang Z; Huang Q; Han L; Fang X; Yang K; Wu S; Zheng Z; Yawalkar N; Wang Z; Yan K
Dermatology; 2021; 237(4):579-587. PubMed ID: 33582672
[TBL] [Abstract][Full Text] [Related]
5. Genetic Polymorphisms of rs9949644 in MAPK4 Are Associated with Clinical Response to Methotrexate in Patients with Psoriasis.
Fan Z; Huang Q; Zhang Z; Han L; Fang X; Yang K; Huang G; Zheng Z; Yawalkar N; Lin Y; Wang Z; Yan K
Dermatology; 2024; 240(1):111-118. PubMed ID: 37494889
[TBL] [Abstract][Full Text] [Related]
6. The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients.
Chen M; Chen W; Liu P; Yan K; Lv C; Zhang M; Lu Y; Qin Q; Kuang Y; Zhu W; Chen X
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2059-2065. PubMed ID: 32271961
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
Singh SK; Singnarpi SR
Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.
Chládek J; Grim J; Martínková J; Simková M; Vanìèková J; Koudelková V; Noièková M
Br J Clin Pharmacol; 2002 Aug; 54(2):147-56. PubMed ID: 12207634
[TBL] [Abstract][Full Text] [Related]
10. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
[TBL] [Abstract][Full Text] [Related]
11. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients.
Tamilselvi E; Haripriya D; Hemamalini M; Pushpa G; Swapna S
Scand J Immunol; 2013 Dec; 78(6):545-53. PubMed ID: 24283773
[TBL] [Abstract][Full Text] [Related]
12. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis.
Dogra S; Singh N; Kumar S; Narang T; Handa S
Dermatol Ther; 2022 Aug; 35(8):e15656. PubMed ID: 35730664
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations within the promotor region of the human histamine H4 receptor gene in psoriasis patients.
Mommert S; Ratz L; Herwig K; Rost M; Gutzmer R; Werfel T
Pharmacol Res; 2016 Dec; 114():121-127. PubMed ID: 27725312
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
15. Effect of methotrexate monotherapy on T-cell subsets in the peripheral circulation in psoriasis.
Priyadarssini M; Chandrashekar L; Rajappa M
Clin Exp Dermatol; 2019 Jul; 44(5):491-497. PubMed ID: 30294828
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
17. Oral fumaric acid esters for psoriasis.
Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Shah S; Nikam B; Kale M; Jamale V; Chavan D
Dermatol Ther; 2021 Jan; 34(1):e14650. PubMed ID: 33296549
[TBL] [Abstract][Full Text] [Related]
19. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
[TBL] [Abstract][Full Text] [Related]
20. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
